Compare Expeditors International of Wshngtn Inc (EXPD) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs McKesson Corporation — how do they compare? Expeditors International of Wshngtn Inc trades at $191.67 (market cap $25.18B), while McKesson Corporation trades at $941.12 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.3× Expeditors International of Wshngtn Inc's market cap, and Expeditors International of Wshngtn Inc pays the higher dividend (0.84%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and McKesson Corporation for 74 Days on average.
| EXPD | MCK | |
|---|---|---|
Market Cap | $25.18B | $108.46B |
Volume | 1,003,557 | 712,607 |
Sector | Industrials | Health |
52-Week High | $194.12 | $995.69 |
52-Week Low | $113.13 | $725.17 |
Typical Hold Time | 43 Days | 74 Days |
Enterprise Value | $24.72B | $115.00B |
Dividend Yield | 0.84% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $193.52, up 1.4% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.20. Revenue grew to $11.07B in 2025, while net income held steady at $810M. The company maintains strong profitability with a 42.6% ROE, though valuation multiples like the 28.2 P/E are elevated relative to historical norms.
Outlook is mixed; efficiency initiatives and airfreight demand support growth, but analyst consensus is cautious with a $179.43 price target below the current price. Key risks include reliance on global trade cycles and potential margin pressure. Upside depends on continued earnings beats and sustained freight market strength.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
